[go: up one dir, main page]

DK0759302T3 - Middel mod rheumatoid arthritis - Google Patents

Middel mod rheumatoid arthritis

Info

Publication number
DK0759302T3
DK0759302T3 DK95913319T DK95913319T DK0759302T3 DK 0759302 T3 DK0759302 T3 DK 0759302T3 DK 95913319 T DK95913319 T DK 95913319T DK 95913319 T DK95913319 T DK 95913319T DK 0759302 T3 DK0759302 T3 DK 0759302T3
Authority
DK
Denmark
Prior art keywords
remedy
rheumatoid arthritis
monoclonal antibody
antibody recognizing
arthritis
Prior art date
Application number
DK95913319T
Other languages
Danish (da)
English (en)
Inventor
Tadashi Nishida
Sachiko Miyake
Ko Okumura
Hideo Yagita
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Application granted granted Critical
Publication of DK0759302T3 publication Critical patent/DK0759302T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK95913319T 1994-04-26 1995-03-22 Middel mod rheumatoid arthritis DK0759302T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8825194 1994-04-26
PCT/JP1995/000527 WO1995028961A1 (fr) 1994-04-26 1995-03-22 Medicament pour polyarthrite rhumatoide

Publications (1)

Publication Number Publication Date
DK0759302T3 true DK0759302T3 (da) 2000-11-13

Family

ID=13937651

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95913319T DK0759302T3 (da) 1994-04-26 1995-03-22 Middel mod rheumatoid arthritis

Country Status (9)

Country Link
US (1) US5855888A (pt)
EP (1) EP0759302B1 (pt)
AT (1) ATE195428T1 (pt)
DE (1) DE69518415T2 (pt)
DK (1) DK0759302T3 (pt)
ES (1) ES2151054T3 (pt)
GR (1) GR3034200T3 (pt)
PT (1) PT759302E (pt)
WO (1) WO1995028961A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347907T1 (de) * 1998-10-07 2007-01-15 Lennart Lindbom Anti-entzündliche alpha2, beta1 integrin- verwandte substanzen oder antikörper
HU226383B1 (hu) * 1999-04-22 2008-10-28 Biogen Idec Inc Eljárás fibrózis kezelésére az integrin alfa-4-alegységének antagonistájával
EP2314315B1 (en) 1999-06-01 2015-01-21 Biogen Idec MA Inc. A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders
US6146639A (en) * 1999-07-26 2000-11-14 Merich Nick Arthritis, muscle pain, and dry skin remedy
AR036330A1 (es) 2001-04-13 2004-09-01 Biogen Inc Un anticuerpo anti-vla-1, una composicion que lo incluye, un acido nucleico aislado consistente en una secuencia de codificacion de dicho anticuerpo, un metodo para determinar el nivel de vla-1 en un tejido, celulas del hibridoma de dicho anticuerpo, una computadora que produce una representacion tr
US20030013107A1 (en) * 2001-06-07 2003-01-16 Rigel Pharmaceuticals, Incorporated Alpha 2 integrin: modulators of lymphocyte activation
PL1948798T3 (pl) * 2005-11-18 2015-12-31 Glenmark Pharmaceuticals Sa Przeciwciała przeciwko integrynie alfa2 i ich zastosowania
ES2509878T3 (es) * 2006-05-25 2014-10-20 Biogen Idec Ma Inc. Anticuerpo anti-VLA-1 para tratar accidente cerebrovascular
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
EP3623381A1 (en) 2011-05-19 2020-03-18 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
EP1715045A3 (en) * 1991-07-25 2006-12-13 Biogen Idec Inc. Recombinant antibodies for human therapy

Also Published As

Publication number Publication date
DE69518415T2 (de) 2001-01-25
EP0759302A1 (en) 1997-02-26
US5855888A (en) 1999-01-05
EP0759302A4 (en) 1997-11-19
WO1995028961A1 (fr) 1995-11-02
GR3034200T3 (en) 2000-11-30
ES2151054T3 (es) 2000-12-16
EP0759302B1 (en) 2000-08-16
DE69518415D1 (de) 2000-09-21
ATE195428T1 (de) 2000-09-15
PT759302E (pt) 2001-01-31

Similar Documents

Publication Publication Date Title
DK0759302T3 (da) Middel mod rheumatoid arthritis
ITMI921522A0 (it) Apparato di lavaggio e sterilizzazione di tappi di gomma, o simili impiegabili in confezioni farmaceutiche
NL300098I1 (nl) Thiophene sulfonamides useful as carbonic anhydrase inhibitors.
ATE192339T1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
ATE138569T1 (de) Topisch anzuwendendes arzneimittel enthaltend ketoprofenlysinat
FI893159A (fi) Laite ja menetelmä terveydenhuollossa syntyvien ongelmajätteiden käsittelemiseksi
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
DE59006506D1 (de) Transdermale Applikation von 2-Amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol.
DE69400338D1 (de) Depigmentierendes Mittel zur gleichzeitigen Behandlung von Hautoberschichten und Hauttiefschichten
ZA969130B (en) Diagnostics and treatments of periodontal disease
BR9406292A (pt) Complexo de inclusão de taxol ou taxotere ou extrato de taxus formados com ciclodextrinas sua preparação e uso
ATE433339T1 (de) Parasympathikomimetikum und parasympathikolytikum enthaltendes tts
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
TNSN95055A1 (fr) Un article absorbant jetable-methode et appareillage pour sa fabrication
FR2713444B1 (fr) Composition liquide désinfectante et ses utilisations.
ATE201828T1 (de) Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung
ES2187618T3 (es) Utilizacion de compuestos de urea y de tiourea para la eliminacion o desintoxicacion de superantigenos de fluidos corporales.
ITRM910545A0 (it) Dispositivo trasportatore di bobine, rocche di filo e simili
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
ES2049711T1 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de la cistinuria.
KR950701812A (ko) 렌티바이러스-유도된 질환의 치료에 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido dervatives useful in the treatment of lentivirus-induced sisease)
ATE222255T1 (de) 14-substituierte marcfortine und derivate als antiparasitäre mittel
FR2690330B1 (fr) Dispositif destine a traiter certaines fractures siegeant entre massif trochanterien et 1/3 moyen de la diaphyse femorale.
DK0826373T3 (da) Forebyggende middel mod postoperativ astigmatisme
IT1266646B1 (it) Dispositivo di chiusura per contenitori,in particolare per contenitori di agenti anestetici